CRSwNP Highlights From the AAO-HNSF 2020 Virtual Meeting

The annual American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNSF) 2020 Meeting was held virtually this year and also included abstracts from the American Rhinologic Society Annual Meeting.

Stella Lee, MD, chief of the Division of Sino-Nasal Disorder and Allergy at the University of Pittsburgh Medical Center, reviews important studies and data presented at the meeting that could have important implications for patient care.

Dr Lee highlights developments in the use of protein biomarkers to help determine potential efficacy of systemic steroid therapy in postsurgical patients with CRSwNP. The study could aid in the prevention of overtreatment in certain patients.

Biologic therapies approved for use in asthma management continue to show efficacy in patients with CRSwNP. The results of the SYNAPSE study of mepolizumab, an anti-IL-5 biologic therapy, showed clear clinical benefit in patients with CRSwNP. The multi-institutional, phase 3 study met primary endpoints and showed that mepolizumab reduced the need for systemic corticosteroid therapy and sinus surgery.

Dr Lee also highlights data from the LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52 phase 3 studies on dupilumab, which indicated efficacy irrespective of the number of prior sinonasal surgeries. Dupilumab also consistently reduced rescue treatment with systemic corticosteroids vs placebo and was well tolerated.

Source Article